NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of LifeMD, Inc. (NASDAQ: LFMD)?Did you purchase your shares between May 7, 2025 and August 5, 2025, inclusive?Did you lose money in your inve ...

NEW YORK , Sept. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD). ...

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the expansion of its state-of-the-art affiliated pharmacy to include advanced non-sterile compounding capabilities for oral and topical medications. This milestone extends LifeMD’s pharmacy growth strategy by enabling its vertically integrated platform to deliver tailored therapies designed to meet evolving patient needs while improving efficiency and reducing relian ...

Accessibility StatementSkip Navigation PHILADELPHIA, Sept. 16, 2025 /PRNewswire/ -- Berger Montague PC, national plaintiffs' law firm, announces a class action lawsuit against LifeMD, Inc. (NASDAQ: LFMD) ("LifeMD" or the "Company") on behalf of investors who purchased or acquired shares during the period from May 7, 2025 through August 5, 2025(the "Class Period"). Investor Deadline: Investors who purchased or acquired LifeMD securities during the Class Period may, no later than October 27, 2025, seek to b ...

LFMD investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants materially overstated LifeMD's competitive position; (2) defendants were reckless in raising LifeMD's 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD's RexMD segment, as well as for customer acquisition cost ...

集体诉讼指控 - 公司面临集体诉讼 指控在2025年5月7日至8月5日期间购买LifeMD证券的投资者可能被误导 [1] - 公司被指控未能披露其竞争地位被夸大 且在提高2025年业绩指引时未合理考虑客户获取成本上升的影响 [2] - 具体涉及RexMD业务部门客户获取成本上升 以及肥胖治疗药物(包括Wegovy和Zepbound)相关的客户获取成本问题 [2] 财务表现与股价影响 - 公司2025年8月5日发布第二季度业绩 承认RexMD业务面临"暂时性挑战"但称已"基本解决" [3] - 公司因此修订2025年全年收入和调整后EBITDA指引 但仍预期这两个指标将实现强劲同比增长 [3] - 该消息导致公司普通股股价单日下跌5.31美元/股 跌幅达44.8% 收盘报6.53美元(2025年8月6日) [3] 公司业务概况 - LifeMD是虚拟初级护理的主要提供商 通过远程医疗平台提供医疗服务 [1] - 公司拥有RexMD业务部门 专注于男性健康领域 包括处方药物的销售 [2]

集体诉讼通知 - 股东集体诉讼针对LifeMD公司 期间为2025年5月7日至2025年8月5日 [3] - 股东需在2025年10月25日前登记参与诉讼 [4] 指控内容 - 公司被指控 materially overstated 其竞争地位 [3] - 公司被指控在未适当考虑客户获取成本上升的情况下 reckless in raising 2025年业绩指引 [3] - 客户获取成本上升涉及RexMD业务部门以及 obesity treatment drugs 包括Wegovy和Zepbound [3] - 公司声明被指控 materially false and misleading 且 lacked a reasonable basis [3] 参与方式 - 股东可通过指定链接登记参与诉讼 [2][4] - 登记后将获得案件进展的 portfolio monitoring software 更新 [4] - 参与诉讼无任何成本或义务 [4]

集体诉讼案件核心指控 - 律师事务所针对LifeMD公司于2025年5月7日至8月5日期间涉嫌发布重大虚假或误导性陈述发起集体诉讼 [1] - 指控公司管理层在三个关键方面存在虚假陈述： materially overstated LifeMD's competitive position [1] - 指控公司 recklessly raised 2025 guidance without properly accounting for rising customer acquisition costs in RexMD segment and for obesity drugs including Wegovy and Zepbound [1] - 指控公司关于业务、运营和前景的陈述 materially false and misleading and/or lacked a reasonable basis at all relevant times [1] 案件程序细节 - 股东参与集体诉讼的登记截止日期为2025年10月25日 [2] - 股东登记后将通过 portfolio monitoring software 获得案件状态更新 [2] - 寻求成为 lead plaintiff 的截止日期为2025年10月25日 [2] 律师事务所背景 - The Gross Law Firm 是一家 nationally recognized class action law firm [3] - 该律所 mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices [3] - 律所致力于确保公司遵守 responsible business practices and engage in good corporate citizenship [3]

NEW YORK, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025, inclusive. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of LifeMD, Inc. (NASDAQ: LFMD)?Did you purchase your shares between May 7, 2025 and August 5, 2025, inclusive ...

诉讼背景 - 针对LifeMD公司的新联邦证券欺诈集体诉讼已在纽约东区提起 指控公司及高管在财务健康状况和增长前景方面误导投资者[1] - 诉讼由Hagens Berman律师事务所主导调查 该所在企业问责复杂诉讼领域已累计获得超过29亿美元赔偿[9] 指控内容 - 公司于2025年5月6日发布第一季度业绩时 提高了全年收入和调整后EBITDA指引 并宣称在虚拟肥胖护理领域拥有"定义类别的竞争护城河"[2] - 指控称公司未披露RexMD部门客户获取成本上升以及体重管理业务退款率高于预期等关键业务挑战[3] - 诉讼重点针对2025年5月7日至8月5日期间公司作出的虚假和误导性陈述[2] 股价影响 - 2025年8月5日公司公布第二季度业绩 收入及每股收益未达预期并下调全年指引 次日股价暴跌超过44%[4] - 管理层在业绩电话会上将原因归咎于RexMD业务"暂时性升高的客户获取成本"和体重管理服务的患者退款问题[4] 诉讼程序 - 集体诉讼期间确定为2025年5月7日至8月5日[2] - 主要原告申请截止日期为2025年10月27日[2] - 潜在赔偿对象涵盖在此期间遭受重大损失的投资者[5]